Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

BACKGROUND: The efficiency and safety of sacituzumab govitecan (SG) for the therapy of hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) metastatic breast cancer (BC) has been demonstrated. The aim of this study is to evaluate its cost-effectiveness on HR+/HER2- metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Demin, Li, Yan, Liang, Xueyan, Chen, Lingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213649/
https://www.ncbi.nlm.nih.gov/pubmed/37251935
http://dx.doi.org/10.3389/fonc.2023.1162360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213649/
https://www.ncbi.nlm.nih.gov/pubmed/37251935
http://dx.doi.org/10.3389/fonc.2023.1162360

Ejemplares similares